U.S. License Holder:
Glaxo Group Ltd.
Date of License:
ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibody indicated:
In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate;
For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL;
For the treatment of patients with CLL refractory to fludarabine and alemtuzumab.